160 related articles for article (PubMed ID: 12843222)
1. Coming of age: recombinant human thyroid-stimulating hormone as a preparation for (131)i therapy in thyroid cancer.
Robbins RJ; Pentlow KS
J Nucl Med; 2003 Jul; 44(7):1069-71. PubMed ID: 12843222
[No Abstract] [Full Text] [Related]
2. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I.
Menzel C; Kranert WT; Döbert N; Diehl M; Fietz T; Hamscho N; Berner U; Grünwald F
J Nucl Med; 2003 Jul; 44(7):1065-8. PubMed ID: 12843221
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
[TBL] [Abstract][Full Text] [Related]
4. A new age for recombinant human thyroid-stimulating hormone?
Medvedec M
J Nucl Med; 2009 May; 50(5):832; author reply 832-3. PubMed ID: 19372486
[No Abstract] [Full Text] [Related]
5. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
6. 131I effective half-life and dosimetry in thyroid cancer patients.
Remy H; Borget I; Leboulleux S; Guilabert N; Lavielle F; Garsi J; Bournaud C; Gupta S; Schlumberger M; Ricard M
J Nucl Med; 2008 Sep; 49(9):1445-50. PubMed ID: 18703593
[TBL] [Abstract][Full Text] [Related]
7. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
[TBL] [Abstract][Full Text] [Related]
8. 131I effective half-life (Teff) for patients with thyroid cancer.
Willegaignon J; Malvestiti LF; Guimarães MI; Sapienza MT; Endo IS; Neto GC; Marone M; Sordi GM
Health Phys; 2006 Aug; 91(2):119-22. PubMed ID: 16832192
[TBL] [Abstract][Full Text] [Related]
9. Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retentions of 131I.
Sisson JC; Shulkin BL; Lawson S
J Nucl Med; 2003 Jun; 44(6):898-903. PubMed ID: 12791816
[TBL] [Abstract][Full Text] [Related]
10. How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer.
Schlumberger M; Ricard M; De Pouvourville G; Pacini F
Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):641-50. PubMed ID: 17710085
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of rhTSH assisted ablation confirmed].
Rausch M
Nuklearmedizin; 2009; 48(6):XII. PubMed ID: 21462568
[No Abstract] [Full Text] [Related]
12. Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer.
Sgouros G
J Nucl Med; 2005 May; 46(5):899-900; author reply 901. PubMed ID: 15872367
[No Abstract] [Full Text] [Related]
13. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
[TBL] [Abstract][Full Text] [Related]
14. Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhTSH.
Lassmann M; Hänscheid H; Reiners C; Thomas SR
J Nucl Med; 2005 May; 46(5):900-1; author reply 901. PubMed ID: 15872369
[No Abstract] [Full Text] [Related]
15. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
16. Value of recombinant human thyrotropin in high-dose radioiodine therapy: a case report.
Müller V; Bohuslavizki KH; Klutmann S; Clausen M
J Nucl Med Technol; 2002 Dec; 30(4):185-8. PubMed ID: 12446752
[TBL] [Abstract][Full Text] [Related]
17. [Endocrinology and nuclear medicine aspects of the treatment of thyroid tumours].
Vicek P
Vnitr Lek; 2007; 53(7-8):807-11. PubMed ID: 17915423
[TBL] [Abstract][Full Text] [Related]
18. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
[TBL] [Abstract][Full Text] [Related]
19. Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin.
Zanotti-Fregonara P; Toubert ME; Taieb D; Ravasi L; Rubello D; Hindie E
Minerva Endocrinol; 2008 Jun; 33(2):53-65. PubMed ID: 18332849
[TBL] [Abstract][Full Text] [Related]
20. Acta Oncologica Lecture. Present status of the use of recombinant human TSH in thyroid cancer management.
Luster M
Acta Oncol; 2006; 45(8):1018-30. PubMed ID: 17118833
[No Abstract] [Full Text] [Related]
[Next] [New Search]
